Researchers have found that low-dose synthetic lycopene alone can suppress the growth of human prostate tumors by over half. A combination of low-dose lycopene and vitamin E was shown to be even more effective in inhibiting tumor growth, with a significant reduction in PSA levels.
Researchers found that Hedgehog activity in localized prostate tumors is significantly lower than in metastatic cancers. Blocking the Hedgehog signal with cyclopamine slowed tumor growth and even reversed aggressive cancer progression in mice experiments.
A study by Thomas Stamey and colleagues found that the correlation between PSA levels and prostate cancer severity has decreased over time, making the test less useful for early detection. Instead, they recommend a yearly digital rectal exam for men over 50.
The Indiana University research team aims to reduce tissue damage from shock wave lithotripsy, a common treatment for kidney stones. They're developing protocols and mathematical models to make the procedure safer and more effective.
A study found that combining testosterone gel with sildenafil improved erectile function in men with low testosterone, who failed to respond to sildenafil alone. The combination therapy showed significant improvements in erectile function, orgasmic function, and overall satisfaction.
Scientists successfully designed and tested nanoparticles to both target and visualize prostate tumors in mice, offering potential for early cancer detection and treatment. The breakthrough uses a unique coating to protect the particles from degradation and enhance their targeting capabilities.
Researchers used gemcitabine and low doses of radiation to treat muscle-invasive bladder cancer in 24 patients. Most were able to keep their bladders intact and were cancer-free after four years, with 65% still cancer-free.
Researchers identified 671 genes with altered expression in prostate cancer tissue, revealing a high degree of similarity between benign adjacent tissue and cancerous tissue. The study found that genetic alterations occur throughout the gland, even in seemingly benign areas, providing new insights into prostate cancer progression.
A study published in NEJM found that rapid rise in PSA levels prior to diagnosis is a stronger indicator of prostate cancer death than the actual PSA level. Early and annual testing are recommended for men with high PSA velocity to detect potential aggressiveness of cancers.
A new study suggests that early hormone therapy can increase survival time by up to 14 years for men with aggressive prostate cancer, compared to those who delay treatment. Prostate cancer affects over 220,000 men annually in the US, with approximately 30,000 dying from the disease each year.
Researchers found that Cox-2 inhibitors slowed disease progression in men with recurrent prostate cancer by inhibiting tumor growth and increasing programmed cell death. The study showed significant results in 22 of 24 patients, with a 92% reduction in PSA levels after three months.
A new study found that hormone deprivation therapy is less effective for younger men with higher grade tumors, suggesting it needs further investigation as an alternative treatment for localized prostate cancer. The study also revealed a higher risk of bone fractures in men on hormone therapy due to osteoporosis.
Researchers found four distinct risk groups and seven independent risk factors for prostate cancer detection, including abnormal exam findings, age, family history, and PSA density. Men with high-risk features remain at risk despite multiple negative biopsies, emphasizing the need for vigilant follow-up.
Dr. Charles Pak, a renowned researcher, has been recognized with an international award for his groundbreaking work on kidney-stone disease treatment methodologies. He has developed several drugs used worldwide and diagnostic methods for measuring risk factors, improving patient outcomes.
Researchers from USC provide a new perspective on treating genetic disorders by switching genes back on using epigenetic therapy. Several chemical compounds have been found to affect epigenetic gene changes and are being tested in clinical trials, including one recently approved for myelodysplastic syndrome.
Research suggests that telomere dysfunction may be a key component in the development of many epithelial cancers. Telomere length abnormalities were observed in 97% of precancerous lesions, with abnormally short telomeres found in 88%.
A new study found that a single daily dose of Valcyte is equally effective as three times daily Cytovene in preventing CMV in kidney transplant patients. This simplified regimen may improve care and quality of life for transplant recipients by reducing medication complexity.
A nationwide study found that patients undergoing kidney cancer surgery at high-volume hospitals have a 32% lower risk of dying compared to those at medium- and low-volume hospitals. High-volume hospitals also performed more partial nephrectomies, a procedure with equally effective cancer control.
Researchers developed two treatments to minimize nerve damage and facilitate nerve recovery, preserving ability to have an erection after radical prostatectomy. Muscle-derived cells and glial cell-derived neurotrophic factors improved erectile function in animal models with cavernous nerve injury.
A University of Pittsburgh study shows Botox injections significantly reduce irritative symptoms and improve quality of life index by 62.3% and 56.5% respectively. Patients experienced increased flow rate and decreased residual urine without significant side effects.
Researchers found that quality of life for men treated for prostate cancer continues to evolve long-term, with some experiencing improvements and others worsening. Sexual function remains a significant concern for survivors, with reported lower quality of life compared to non-cancerous individuals.
Researchers at the University of Pittsburgh have identified a potential biomarker, RCCA-5, which may help detect renal cell carcinoma in its early stages. Early detection is crucial for effective treatment, and RCCA-5 shows promise as an effective marker for urologic cancers.
A study by Mount Sinai School of Medicine found that brachytherapy effectively treats prostate cancer while preserving quality of life. The research team followed 255 patients with prostate cancer treated with I-125 and reported minimal urinary symptoms, preserved potency, and reduced bleeding.
A six-year study by University of Pittsburgh researcher found botox injections to be a safe and effective treatment for bladder dysfunction, reducing incontinence in 67.2% of patients. The therapy works by blocking muscle contractions, restoring normal bladder function and improving quality of life.
Moderately and severely obese patients experienced higher Gleason scores and rising PSA levels after surgery, indicating aggressive prostate cancer. Men with a BMI of greater than 35 kg/m2 had a 60% risk of cancer recurrence within three years.
A UMHS study found that African-American men with a history of gonorrhea are more likely to develop prostate cancer. The research suggests an inflammatory effect from the bacterial infection may trigger pre-existing cancerous cells to multiply, increasing risk.
Researchers have identified a new biomarker, EPCA, which may enable early detection and treatment of prostate cancer. The study found that EPCA was expressed in tissue samples from patients with prostate cancer who initially had negative biopsies.
A University of Pittsburgh study found that women with overactive bladder experience reduced sexual function and thoughts. Overactive bladder affects half of the 17 million Americans suffering from it, significantly impacting their quality of life.
Researchers found a significant association between high blood testosterone levels and an increased risk of prostate cancer in older men. The study, which followed over 3,000 men for 40 years, also showed that the protein sex hormone-binding globulin (SHBG) was associated with a slightly decreased risk for prostate cancer.
A study found that robotic doctor visits increased patient comfort and accessibility to medical information, with 57% suggesting it should become a standard practice. Patients preferred having their own physician conduct telerounds over others.
A new study published in Urology found that men taking AVODART for four years experienced a significant reduction in urinary symptoms and prostate volume, with an average symptom improvement of 6.1 points on the AUA-SI. Long-term treatment also resulted in low incidence of drug-related side effects.
A new online tool provides personalized 10-year survival predictions for prostate cancer patients, taking into account age, race, co-morbidities, and treatment type. The model also highlights the significant impact of co-morbidities on long-term survival rates.
Researchers found that men with a family history of prostate cancer can accurately assess their lifetime risk and are more likely to use supplements to improve their health. The study also reveals that younger brothers of men with prostate cancer are nearly four times more likely to report using complementary or alternative medicine.
A recent UMHS study found that black men with moderate-grade prostate cancer are 36% less likely to receive treatment than white men. Hispanic men also face disparities in treatment, with 16% fewer chances of receiving definitive therapy compared to white men.
A study found that mutated tumor suppressor genes, particularly p53 and p21, play a significant role in bladder cancer development. Eighty bladder cancer patients were evaluated, and the researchers discovered that these genes are altered in 83 percent of patients.
A new biomarker, EPCA, has been discovered that can detect prostate cancer earlier than traditional methods. The marker is expressed in the tumor and throughout the prostate in men with prostate cancer.
Researchers at Mayo Clinic developed a pretreatment test to identify patients at high risk for urinary tract difficulties after brachytherapy. The study found that 37% of high-risk patients developed some urinary difficulties, while 85% of low-risk patients did not experience problems.
Two studies found obesity increases risk of aggressive prostate cancer and cancer recurrence in African-American men. Obesity is associated with higher Gleason scores and elevated PSA levels, suggesting a link between excess body fat and tumor growth.
Researchers are investigating the role of broccoli-derived chemicals in preventing prostate cancer. The study aims to better understand how these substances inhibit prostate cancer growth and identify potential biomarkers for future intervention trials.
A double-blind study found that combination therapy with finasteride and doxazosin significantly delayed BPH progression in men with symptomatic BPH. The treatment reduced the risk of acute urinary retention and need for surgical intervention by over 65%.
A study found that nearly one-third of online bladder cancer information is outdated and inaccurate, with limited information on treatment options and follow-up care. The researchers recommend using reliable sources such as the National Cancer Institute and MEDLINEplus for accurate information.
A study found that 29.8% of Ontario men diagnosed with prostate cancer used complementary medicine, highlighting the need for awareness and discussion among clinicians. The most commonly used products were natural health supplements like vitamin E, saw palmetto, and selenium, which may interact with conventional therapies.
A team led by Queen's urologist Dr. J. Curtis Nickel will investigate herbal remedies like saw palmetto and pygeum africanum for treating BPH, prostatitis, and bladder disease. The study aims to determine the true effectiveness and safety of these alternative therapies.
A new procedure using cryotherapy has been shown to effectively reduce the size of benign breast lumps by an average of 73% without significant complications. Patients report satisfactory cosmetic results and a high level of patient acceptance for this non-invasive treatment.
Researchers at UCL's Wolfson Institute for Biomedical Research have developed a new drug to treat enlarged prostate with virtually no hormonal side effects. The treatment can both relax the prostate and prevent its growth, offering a major advance in treating a condition affecting millions of men worldwide.
Researchers will study the biology of tumor-stroma interaction, heparan sulfate proteoglycans in bone metastasis, and mitochondrial DNA mutations to develop novel diagnostic and therapeutic strategies. The goal is to understand how prostate cancer cells metastasize to bone and discover new genes that may support or inhibit this process.
A UCLA study found 54 genes produced differently in male and female mouse brains prior to hormonal influence, suggesting genetic influences on sexual differences. The research may help explain why people feel male or female and inform the development of treatments for intersex infants.
A UB research study found that sperm from marijuana smokers exhibit abnormal swimming behavior, moving too fast and too early, which can lead to infertility. The study suggests that THC may be causing improper timing of sperm function or bypassing natural inhibition mechanisms.
The study evaluated 27 surgeons in 23 centers and found that quality of surgery is independent of caseload. The parameters used included length of surgery, blood loss, postoperative continence, and PSA levels after surgery.
A study found that Viagra took effect within 14-20 minutes for many men, with over half experiencing erections leading to successful intercourse. The medication was well-tolerated, with no patients discontinuing treatment due to side effects.
The article describes a biologically well-characterized mouse model for cystinuria type I, a human disease caused by impaired renal function. The model closely mimics the human disease state and is expected to improve biomedical research in areas like disease analysis and drug testing.
A new study reveals that patients who received neoadjuvant chemotherapy lived an average of 31 months longer than those treated with surgery alone. The combination therapy showed a 66% greater chance of surviving bladder cancer.
A University of Iowa Health Care study found that public elementary school teachers often restrict young students' access to the bathroom, despite it being a common issue. Teachers with more experience were better equipped to recognize bladder problems and involved school nurses in addressing them.
A new study suggests that telomere dysfunction may play a causal role in human intraepithelial neoplasia (IEN) found in precancers. Short telomeres were found in the majority of precursor lesions across various types of cancers, indicating potential early molecular mechanisms underlying cancer development.
Researchers used blood samples to analyze protein patterns and determine if biopsies were necessary. The test showed a sensitivity of 100% and specificity of 67%, suggesting it could save over 50% of biopsies. The study's results may lead to more accurate cancer detection and tailored therapy for individual patients.
A new study by UT Southwestern finds that finasteride effectively reduces prostate cancer risk and improves symptoms in men with benign prostatic hyperplasia. The drug, already used to treat BPH, works by inhibiting the conversion of testosterone to dihydrotestosterone, which is involved in prostate cancer development.
Researchers discovered a core set of essential genes that universally activate in human cancer, regardless of tissue origin. The findings suggest these genes are prime targets for new cancer-fighting drugs.
Researchers found that nearly half of men with elevated PSA levels had returned to normal levels after a year or more, making unnecessary biopsies possible. Repeating the PSA test after waiting at least six weeks may reduce unnecessary procedures and small incidental tumors.
A UC Davis study found that a soy extract supplement reduced PSA levels in men with untreated prostate cancer. The study involved 62 men who received genistein concentrated polysaccharide for six months, resulting in an average decrease of 17% in PSA levels.
Researchers have discovered that injecting herpes simplex virus vectors can deliver neurotrophic factors to damaged nerves, improving intracavernous pressure in rats. This concept could translate to humans, enabling gene therapy as a prophylactic treatment for men undergoing radical prostatectomy.